
PEA2 Cell Line Product
PEA2 cell line: One of nine from the PE ovarian adenocarcinoma panel. Adherent cell collected on relapse after treatment with cisplatin and prednimustine.
Showing results for pea1 pea2 peo 20152107 20152107 20152107 20152107 20152107 20152107 peo 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107
PEA2 cell line: One of nine from the PE ovarian adenocarcinoma panel. Adherent cell collected on relapse after treatment with cisplatin and prednimustine.
PEA1 is an adherent cell line derived from a malignant effusion from the pleural cavity of a patient with a poorly differentiated adenocarcinoma.
[…] HR competence. Studying this evolution is key to understanding and overcoming acquired drug resistance. The PEO series uniquely models this trajectory. PEO1, PEO4, and PEO6 were derived from the same […]
[…] toxicity testing and cancer genetic studies, and its isogenic drug-resistant derivatives. Our collection also includes PEO4, part of the nine PE ovarian adenocarcinoma cell line panel derived from patients at […]
PEO16 cell line: Collected after radiotherapy. Part of the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer).
The PEO1-CDDP Cell Line is an in-vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance.
[…] with a well differentiated serous adenocarcinoma. This cell line is from the same patient as PEO14 and PEO23 cell lines and is a oestrogen receptor negative cell line. TO14 cell […]
PEO23 was collected on relapse after cisplatin and chlorambucil treatment. PEO23 exhibits poor growth in semi-solid medium (agar). PEO23 is from the same patient asTO14 cell lines.
The PEO14 cell line is one of nine from the PE ovarian adenocarcinoma panel – derived from 4 patients at varying stages of ovarian cancer
PEO6 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.